European biotech and medtech companies have a new source of growth capital to tap. Sofinnova Partners, which has for the past four decades focused on seed and series A venture funding of life science start-ups, has launched the Sofinnova Crossover I fund with €275M ($340M) to finance cash thirsty later stage biotech and medtech companies.
“Raising money in seed and series A rounds has never been easier for European life science start-ups. The challenge they...






